Late Qing parliamentarism and the borderlands of the Qing Empire—Mongolia, Tibet, and Xinjiang (1906–1911)

Egas Moniz Bandeira 한양대학교 아태지역연구센터 2020 Journal of Eurasian Studies Vol.11 No.1

The article examines the relationship between the late Qing constitutional movement of 1905–1911 and the vast borderland regions of the Qing Empire–that is, Mongolia, Tibet, and Xinjiang. It traces how intellectuals and officials concerned with devising constitutional policies foresaw the integration of these regions into the nascent parliamentary institutions at the provincial and central levels. The article argues that the status of the borderlands played a significant role in late Qing constitutional debates, and that debates on borderland constitutionalism were a phenomenon of a wider constitutional wave affecting Eurasia in the 1900s. Chinese intellectuals and officials felt the competition of the emerging parliamentary institutions in Russia and the Ottoman Empire, and anticipating that constitutional and parliamentarist movements among Mongols, Tibetans, and Turki could lead to the separation of the respective regions, they hoped that parliamentary representation, albeit limited, would be an instrument against centrifugal tendencies on the borders. Hence, they called for constitutional reforms in China and for the inclusion of the borderland populations into the new parliamentary institutions. Yet, arguing with the sparse population of the borderlands as well as with their alleged economic and cultural backwardness, they denied the direct application of the constitutional plan to these territories. The differentiated policies eventually applied to the borderlands were a lackluster compromise between these conflicting interests.

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review

Arthur Costa Inojosa,Laís Mendes,Leonardo Bandeira,Francisco Bandeira 대한골대사학회 2022 대한골대사학회지 Vol.29 No.4

Denosumab is a potent anti-resorptive medication used to treat patients at high risk for osteoporosis; however, its beneficial effects on the skeletal system are quickly reversed after discontinuation. In contrast, bisphosphonates (BPs) are anti-resorptive agents with residual effects on the bone matrix; thus, these are capable of preserving bone mass for a long time. Therefore, subsequent anti-resorptive treatment with BPs is mandatory to prevent rebound fractures. Furthermore, BP administration before denosumab treatment appears to be a reasonable strategy for reducing hyperactivation of bone remodeling. In this review, we summarize the effects of BP administration before denosumab treatment in preventing rebound fractures after denosumab discontinuation.

Fast Multi-blind Modification Search through Tandem Mass Spectrometry

Na, Seungjin,Bandeira, Nuno,Paek, Eunok American Society for Biochemistry and Molecular Bi 2012 Molecular and Cellular Proteomics Vol.11 No.4

Human Proteome Project Mass Spectrometry Data Interpretation Guidelines 3.0

Deutsch, Eric W.,Lane, Lydie,Overall, Christopher M.,Bandeira, Nuno,Baker, Mark S.,Pineau, Charles,Moritz, Robert L.,Corrales, Fernando,Orchard, Sandra,Van Eyk, Jennifer E.,Paik, Young-Ki,Weintraub, S American Chemical Society 2019 JOURNAL OF PROTEOME RESEARCH Vol.18 No.12

<P>The Human Proteome Organization’s (HUPO) Human Proteome Project (HPP) developed Mass Spectrometry (MS) Data Interpretation Guidelines that have been applied since 2016. These guidelines have helped ensure that the emerging draft of the complete human proteome is highly accurate and with low numbers of false-positive protein identifications. Here, we describe an update to these guidelines based on consensus-reaching discussions with the wider HPP community over the past year. The revised 3.0 guidelines address several major and minor identified gaps. We have added guidelines for emerging data independent acquisition (DIA) MS workflows and for use of the new Universal Spectrum Identifier (USI) system being developed by the HUPO Proteomics Standards Initiative (PSI). In addition, we discuss updates to the standard HPP pipeline for collecting MS evidence for all proteins in the HPP, including refinements to minimum evidence. We present a new plan for incorporating MassIVE-KB into the HPP pipeline for the next (HPP 2020) cycle in order to obtain more comprehensive coverage of public MS data sets. The main checklist has been reorganized under headings and subitems, and related guidelines have been grouped. In sum, Version 2.1 of the HPP MS Data Interpretation Guidelines has served well, and this timely update to version 3.0 will aid the HPP as it approaches its goal of collecting and curating MS evidence of translation and expression for all predicted ∼20 000 human proteins encoded by the human genome.</P> [FIG OMISSION]</BR>

Primary somatosensory cortex and periaqueductal gray functional connectivity as a marker of the dysfunction of the descending pain modulatory system in fibromyalgia

Matheus Soldatelli,Álvaro de Oliveira Franco,Felipe Picon,Juliana Ávila Duarte,Ricardo Scherer,Janete Bandeira,Maxciel Zortea,Iraci Lucena da Silva Torres,Felipe Fregni,Wolnei Caumo 대한통증학회 2023 The Korean Journal of Pain Vol.36 No.1

Background: Resting-state functional connectivity (rs-FC) may aid in understanding the link between painmodulating brain regions and the descending pain modulatory system (DPMS) in fibromyalgia (FM). This study investigated whether the differences in rs-FC of the primary somatosensory cortex in responders and non-responders to the conditioned pain modulation test (CPM-test) are related to pain, sleep quality, central sensitization, and the impact of FM on quality of life. Methods: This cross-sectional study included 33 females with FM. rs-FC was assessed by functional magnetic resonance imaging. Change in the numerical pain scale during the CPM-test assessed the DPMS function. Subjects were classified either as non-responders (i.e., DPMS dysfunction, n = 13) or responders (n = 20) to CPM-test. A generalized linear model (GLM) and a receiver operating characteristic (ROC) curve analysis were performed to check the accuracy of the rs-FC to differentiate each group. Results: Non-responders showed a decreased rs-FC between the left somatosensory cortex (S1) and the periaqueductal gray (PAG) (P < 0.001). The GLM analysis revealed that the S1-PAG rs-FC in the left-brain hemisphere was positively correlated with a central sensitization symptom and negatively correlated with sleep quality and pain scores. ROC curve analysis showed that left S1-PAG rs-FC offers a sensitivity and specificity of 85% or higher (area under the curve, 0.78, 95% confidence interval, 0.63–0.94) to discriminate who does/does not respond to the CPM-test. Conclusions: These results support using the rs-FC patterns in the left S1-PAG as a marker for predicting CPM-test response, which may aid in treatment individualization in FM patients.

Unfavorable Vascular Anatomy during Endovascular Treatment of Stroke: Challenges and Bailout Strategies

Francisco José Arruda Mont`Alverne,Fabricio Oliveira Lima,Felipe de Araújo Rocha,Diego de Almeida Bandeira,Adson Freitas de Lucena,Henrique Coelho Silva,이진수,Raul Gomes Nogueira 대한뇌졸중학회 2020 Journal of stroke Vol.22 No.2

The benefit of mechanical thrombectomy (MT) in acute ischemic stroke (AIS) due to large vessel intracranial occlusions is directly related to the technical success of the procedures in achieving fast and complete reperfusion. While a precise definition of refractoriness is lacking in the literature, it may be considered when there is reperfusion failure, long procedural times, or high number of passes with the MT devices. Detailed knowledge about the causes for refractory MT in AIS is limited; however, it is most likely a multifaceted problem including factors related to the vascular anatomy and the underlying nature of the occlusive lesion amongst other factors. We aim to review the impact of several key unfavorable anatomical factors that may be encountered during endovascular AIS treatment and discuss potential bail-out strategies to these challenging situations.

Effects of the Use of Beta-Blockers on Chronic Obstructive Pulmonary Disease Associated with Cardiovascular Comorbities: Systematic Review and Meta-analysis

( Natasha Cordeiro Dos Santos ),( Aquiles Assunção Camelier ),( Anne Karine Menezes ),( Victor Durier Cavalcanti De Almeida ),( Roberto Rodrigues Bandeira Tosta Maciel ),( Fernanda Warken Rosa Camelie 대한결핵 및 호흡기학회 2024 Tuberculosis and Respiratory Diseases Vol.87 No.3

Cardiovascular comorbidity is common in individuals with chronic obstructive pulmonary disease (COPD). This factor interferes with pharmacological treatment. The use of β-blockers has been proposed for their known cardioprotective effects. However, due to their adverse reactions, and the risk of causing bronchospasm, there is reluctance to use them. To summarize existing evidence on the effects of β-blocker use in COPD associated with cardiovascular comorbidities in relation to disease severity, exacerbation, and mortality outcomes. EMBASE, Medline, Lilacs, Cochrane Library, and Science Direct databases were used. Observational studies that evaluated the effects of β-blockers on individuals with COPD and cardiovascular comorbidities, and related disease severity, exacerbations, or mortality outcomes were included. Studies that did not present important information about the sample and pharmacological treatment were excluded. Twenty studies were included. Relevance to patient care and clinical practice: The use of β-blockers in individuals with COPD and cardiovascular disease caused positive effects on mortality and exacerbations outcomes, compared with the results of individuals who did not use them. The severity of the disease caused a slight change in forced expiratory volume in 1 second. The odds ratio for mortality was 0.50 (95% confidence interval [CI], 0.39 to 0.63; p<0.00001), and for exacerbations, 0.76 (95% CI, 0.62 to 0.92; p=0.005), being favorable to the group that used β-blockers. Further studies are needed to study the effect of using a specific β-blocker in COPD associated with a specific cardiovascular comorbidity.

Prevalence and Impact of Comorbidities in Individuals with Chronic Obstructive Pulmonary Disease: A Systematic Review

Natasha Cordeiro dos Santos,Marc Miravitlles,Aquiles Assunção Camelier,Victor Durier Cavalcanti de Almeida,Roberto Rodrigues Bandeira Tosta Maciel,Fernanda Warken Rosa Camelier 대한결핵및호흡기학회 2022 Tuberculosis and Respiratory Diseases Vol.85 No.3

This study aimed to describe the prevalence of comorbidities associated with chronic obstructive pulmonary disease (COPD) and their relation with relevant outcomes. A systematic review based on the PRISMA methodology was performed from January 2020 until July 2021. The MEDLINE, Lilacs, and Scielo databases were searched to identify studies related to COPD and its comorbidities. Observational studies on the prevalence of comorbidities in COPD patients and costs with health estimates, reduced quality of life, and mortality were included. Studies that were restricted to one or more COPD pain assessments and only specific comorbidities such as osteoporosis, bronchitis, and asthma were excluded. The initial search identified 1,409 studies and after applying the inclusion and exclusion criteria, 20 studies were finally selected for analysis (comprising data from 447,459 COPD subjects). The most frequent COPD comorbidities were: hypertension (range, 17%–64.7%), coronary artery disease (19.9%–47.8%), diabetes (10.2%–45%), osteoarthritis (18%–43.8%), psychiatric conditions (12.1%–33%), and asthma (14.7%–32.5%). Several comorbidities had an impact on the frequency and severity of COPD exacerbations, quality of life, and mortality risk, in particular malignancies, coronary artery disease, chronic heart failure, and cardiac arrhythmias. Comorbidities, especially cardiovascular diseases and diabetes, are frequent in COPD patients, and some of them are associated with higher mortality.

Vitamin D Deficiency in Patients Hospitalized for Heart Failure Living in the Tropics

de Oliveira Lucian Batista,de Figueiredo Martins Siqueira Mariana Andrade,de Macedo Gadêlha Rafael Buarque,Garcia Jessica,Bandeira Francisco 대한심부전학회 2024 International Journal of Heart Failure Vol.6 No.2

Background and Objectives Vitamin D, as a steroid hormone, has multiple effects on human body and its deficiency has been associated with an increased risk of heart failure (HF) and unfavorable outcomes. The present study investigated the prevalence of vitamin D deficiency (VDD) and its relationship with cardiometabolic parameters in patients hospitalized for HF living in the city of Recife (latitude 8° South). Methods Analytical cross-sectional study, with men and women aged 40–64 years. The HF group was recruited during hospitalization due to decompensation. A matched control group was recruited from the general endocrine clinics. Vitamin D status was assessed by measuring serum 25-hydroxyvitamin D (25OHD), considering deficiency when 25OHD <20 ng/mL (<50 nmol/L). Results A total of 243 patients were evaluated (HF group: 161, control group: 82). Lower serum 25OHD levels were observed in the HF group (25.2±9.4 vs. 30.0±7.7ng/mL; p<0.001), as well as a higher prevalence of VDD (27.3% vs. 9.8%; prevalence ratio, 2.80; 95% confidence interval, 1.38–5.67; p=0.002). In patients with HF, VDD was associated with diabetes mellitus (65.9% vs. 41.0%; p=0.005) and female sex (65.9% vs. 44.4%; p=0.015). In the subgroup with VDD, higher values of hemoglobin A1c (7.9% [6.0–8.9] vs. 6.2% [5.7–7.9]; p=0.006) and dyslipidemia were also observed. Conclusions We found higher rates of VDD in patients hospitalized for HF and this was associated with deleterious laboratory metabolic parameters. Background and Objectives Vitamin D, as a steroid hormone, has multiple effects on human body and its deficiency has been associated with an increased risk of heart failure (HF) and unfavorable outcomes. The present study investigated the prevalence of vitamin D deficiency (VDD) and its relationship with cardiometabolic parameters in patients hospitalized for HF living in the city of Recife (latitude 8° South). Methods Analytical cross-sectional study, with men and women aged 40–64 years. The HF group was recruited during hospitalization due to decompensation. A matched control group was recruited from the general endocrine clinics. Vitamin D status was assessed by measuring serum 25-hydroxyvitamin D (25OHD), considering deficiency when 25OHD <20 ng/mL (<50 nmol/L). Results A total of 243 patients were evaluated (HF group: 161, control group: 82). Lower serum 25OHD levels were observed in the HF group (25.2±9.4 vs. 30.0±7.7ng/mL; p<0.001), as well as a higher prevalence of VDD (27.3% vs. 9.8%; prevalence ratio, 2.80; 95% confidence interval, 1.38–5.67; p=0.002). In patients with HF, VDD was associated with diabetes mellitus (65.9% vs. 41.0%; p=0.005) and female sex (65.9% vs. 44.4%; p=0.015). In the subgroup with VDD, higher values of hemoglobin A1c (7.9% [6.0–8.9] vs. 6.2% [5.7–7.9]; p=0.006) and dyslipidemia were also observed. Conclusions We found higher rates of VDD in patients hospitalized for HF and this was associated with deleterious laboratory metabolic parameters.